| Englischer Name | Forschungscode | Forschungsphase | Firma | Indikationen | Klinische Studie |
|---|---|---|---|---|---|
| Ipsoprubart | ELA-026 | Phase 3 Clinical | Electra Therapeutics Inc | Lymphohistiocytosis, Hemophagocytic; Neoplasms | Details |
| LM-101 | LM-101 | Phase 2 Clinical | LaNova Medicines Ltd | Hematologic Neoplasms; Leukemia; Neoplasms; Solid tumours | Details |
| HX-044 | HX044; HX-044 | Phase 2 Clinical | Hanx Biopharmaceuticals Pty Ltd | Lymphoma; Solid tumours | Details |
| BRB-002 | BRB-002 | Phase 2 Clinical | Bitterroot Bio Inc | Atherosclerosis; Cardiovascular Diseases; Vasculitis | Details |
| BI-770371 | BI-770371 | Phase 2 Clinical | Ose Immunotherapeutics | Carcinoma, Non-Small-Cell Lung; Liver Cirrhosis; Melanoma; Metabolic Dysfunction-Associated Steatotic Liver Disease; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details |
| IBC-0966 | IBC-0966 | Phase 2 Clinical | Neoplasms | Details | |
| HX-009 | HX-009; HX009-II-02 | Phase 2 Clinical | Waterstone Hanxbio Pty Ltd | Bile Duct Neoplasms; Biliary Tract Neoplasms; Liver Neoplasms; Lymphoma; Melanoma; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms | Details |
| BI-765063 | OSE-172; BI-765063; Effi-DEM | Phase 1 Clinical | Effimune | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Melanoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details |
| ADU-1805 | ADU-1805 | Phase 1 Clinical | Aduro Biotech Inc | Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Neoplasms; Solid tumours | Details |
| Q-1801 | Q-1801; Q 1801 | Phase 1 Clinical | Qure Biotechnology (Shanghai) Co Ltd | Solid tumours | Details |
| Recombinant humanized IgG4 anti-SIRPα antibody(Daiichi Sankyo) | DS-1103a | Phase 1 Clinical | Daiichi Sankyo Co Ltd | Breast Neoplasms; Solid tumours | Details |
| JY-47 | JY47; JY-47 | Phase 1 Clinical | Hangzhou Jiuyuan Gene Biomedical Co Ltd | Liver Cirrhosis; Metabolic Dysfunction-Associated Steatotic Liver Disease; Solid tumours | Details |
| BYON-4228 | BYON-4228 | Phase 1 Clinical | Sanquin Blood Supply Foundation | Lymphoma; Solid tumours | Details |
| BSI-082 | BSI-082 | Phase 1 Clinical | Biosion Inc | Hematologic Neoplasms; Neoplasm Metastasis; Solid tumours | Details |
| BR-105 | BR-105; BR105 | Phase 1 Clinical | Hisun Biopharmaceutical Co Ltd, Zhejiang BioRay Biopharmaceuticals Co Ltd | Lymphoma, Large B-Cell, Diffuse; Neoplasms | Details |
| [89Zr]Zr- BI-765063(Boehringer Ingelheim) | Phase 1 Clinical | Boehringer Ingelheim Corp | Carcinoma, Non-Small-Cell Lung; Melanoma; Squamous Cell Carcinoma of Head and Neck | Details | |
| TQB-2928 | TQB-2928 | Phase 1 Clinical | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung; Hematologic Neoplasms; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Neoplasms; Osteosarcoma; Solid tumours | Details |
| BI-765080 | Phase 1 Clinical | C.H. Boehringer Sohn Ag & Co. Kg | Details | ||
| ES-004 | ES-004; ES 004-N4; ES 004-B4 | Phase 1 Clinical | Elpiscience (Shanghai) Biopharma Ltd | Neoplasms; Solid tumours | Details |
| Englischer Name | Forschungscode | Forschungsphase | Firma | Frühestes Markenname | Frühestes Genehmigungsland | Früheste Indikation | Früheste Genehmigungsgesellschaft | Früheste Genehmigungsdatum | Indikationen | Klinische Studie |
|---|---|---|---|---|---|---|---|---|---|---|
| Relugolix/Estradiol/Norethindrone Acetate | E2/NETA | Approved | Myovant Sciences | MYFEMBREE, RYEQO | United States | Menorrhagia; Leiomyoma | Sumitomo Pharma America Inc, Myovant Sciences | 2021-05-26 | Endometriosis; Leiomyoma; Menorrhagia; Pain; Uterine Neoplasms | Details |
| Elagolix/estradiol/norethindrone acetate | Approved | Abbvie Inc | Oriahnn | United States | Menorrhagia | Abbvie Inc | 2020-05-29 | Menorrhagia | Details |